OAB-14 Effectively Ameliorates the Dysfunction of the Endosomal-Autophagic-Lysosomal Pathway in APP/PS1 Transgenic Mice.
ACS Chem Neurosci
; 12(21): 3985-3993, 2021 11 03.
Article
em En
| MEDLINE
| ID: mdl-34652916
ABSTRACT
In Alzheimer's disease (AD), damaged Aß clearance contributes to elevated levels of Aß that cause a series of cytotoxic cascade reactions. Thus, targeting Aß clearance has now been considered a valid therapeutic approach for AD. Cellular uptake and degradation are important mechanisms for Aß clearance, which are mainly performed by the endosomal-autophagic-lysosomal (EAL) pathway. Our previous study showed that OAB-14, a novel small molecule designed with bexarotene as the lead compound, treatment for 3 months significantly alleviated cognitive disorders and remarkably reduced the deposition of Aß without affecting its production in APP/PS1 transgenic mice. Here, we further revealed that enhancement of the EAL activity is one of the mechanisms that increases Aß clearance after OAB-14 administration for 3 months. OAB-14 facilitates receptor-mediated endocytosis and restores autophagy flux via the AMPK/mTOR pathway. Meanwhile, OAB-14 enhances the lysosomal activity, and reduced Aß accumulation in lysosomes was observed in OAB-14-treated AD mice. These results suggest that OAB-14 may promote Aß clearance in lysosomes by alleviating the EAL dysfunction in AD mice.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeos beta-Amiloides
/
Doença de Alzheimer
Limite:
Animals
Idioma:
En
Revista:
ACS Chem Neurosci
Ano de publicação:
2021
Tipo de documento:
Article